1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > U.S. Stem Cell, Inc. (USRM) - Medical Equipment - Deals and Alliances Profile

Summary

U.S. Stem cell, Inc., (formerly Bioheart, Inc.) is a biotechnology company which focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal function. The company’s lead product MyoCell, is designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, to improve cardiac function in chronic heart failure patients. Its services includes the development of proprietary cell therapy products based on regenerative medicine and cell therapy training services, cell collection and cell storage services, sale of cell collection and treatment kits for humans and animals, and operation of a cell therapy clinic. U.S. Stem cell is headquartered in Florida, the US.

U.S. Stem Cell, Inc. (USRM) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

U.S. Stem Cell, Inc. (USRM) - Medical Equipment - Deals and Alliances Profile
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
U.S. Stem Cell, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 5
U.S. Stem Cell, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 6
U.S. Stem Cell, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 7
U.S. Stem Cell, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 8
U.S. Stem Cell, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 9
U.S. Stem Cell, Inc., Medical Equipment, Deal Details 10
Partnerships 10
Bioheart Extends Licensing Agreement With Airspeed Equity 10
Bioheart Enters Into Licensing Agreement With Airspeed Equity 11
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 12
Equity Offering 13
Bioheart to Raise USD3 Million in Private Placement of Shares 13
Bioheart Completes Private Placement Of Shares For US$3 Million 14
Bioheart Completes Private Placement Of Shares 15
Bioheart Announces Private Placement Of Shares For US$2 Million 16
Bioheart Receives Equity Investment From AnC Bio Holdings 17
Debt Offering 18
Bioheart Raises USD3 Million in Private Placement of Notes 18
Acquisition 19
Bioheart to Acquire Pavillion Scientific 19
Bioheart to Invest in Ascyrus Medical 20
U.S. Stem Cell, Inc. - Key Competitors 21
Key Employees 22
Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
May 06, 2015: Bioheart Highlights Positive First Quarter Results 24
Corporate Communications 25
Jan 29, 2015: Bioheart Strengthens Management Team with Appointment of Martin E. Schmieg as President of Vetbiologics 25
Other Significant Developments 26
Aug 27, 2015: Bioheart to Change Name to U.S. Stem Cell, Inc. 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
U.S. Stem Cell, Inc., Medical Equipment, Key Facts, 2015 1
U.S. Stem Cell, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 1
U.S. Stem Cell, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 5
U.S. Stem Cell, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 6
U.S. Stem Cell, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 7
U.S. Stem Cell, Inc., Deals By Market, 2010 to YTD 2016 8
U.S. Stem Cell, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 9
Bioheart Extends Licensing Agreement With Airspeed Equity 10
Bioheart Enters Into Licensing Agreement With Airspeed Equity 11
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 12
Bioheart to Raise USD3 Million in Private Placement of Shares 13
Bioheart Completes Private Placement Of Shares For US$3 Million 14
Bioheart Completes Private Placement Of Shares 15
Bioheart Announces Private Placement Of Shares For US$2 Million 16
Bioheart Receives Equity Investment From AnC Bio Holdings 17
Bioheart Raises USD3 Million in Private Placement of Notes 18
Bioheart to Acquire Pavillion Scientific 19
Bioheart to Invest in Ascyrus Medical 20
U.S. Stem Cell, Inc., Key Competitors 21
U.S. Stem Cell, Inc., Key Employees 22

List of Figures
U.S. Stem Cell, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016 1
U.S. Stem Cell, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 1
U.S. Stem Cell, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 1
U.S. Stem Cell, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 1
U.S. Stem Cell, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 5
U.S. Stem Cell, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016 6
U.S. Stem Cell, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 7
U.S. Stem Cell, Inc., Medical Equipment, Deals by Market, 2010 to YTD 2016 8

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glial Cell Line Derived Neurotrophic Factor (Astrocyte ...

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016

  • $ 2500
  • Company report
  • October 2016
  • by Global Markets Direct

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016, ...

Ageing - Pipeline Review, H2 2016

October 2016 $ 2000

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.